Business Description
iBio Inc
NAICS : 325412
SIC : 2834
ISIN : US4510332038
Description
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.61 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.24 | |||||
| Debt-to-EBITDA | -0.33 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -17.68 | |||||
| Beneish M-Score | -1.16 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -78.7 | |||||
| 3-Year EBITDA Growth Rate | 57.3 | |||||
| 3-Year EPS without NRI Growth Rate | 63.2 | |||||
| 3-Year FCF Growth Rate | 62.1 | |||||
| 3-Year Book Growth Rate | -78.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 43.25 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.37 | |||||
| Quick Ratio | 3.37 | |||||
| Cash Ratio | 3.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -170.5 | |||||
| Shareholder Yield % | -69.18 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -8935.43 | |||||
| Net Margin % | -13228.57 | |||||
| FCF Margin % | -9529.45 | |||||
| ROE % | -134.05 | |||||
| ROA % | -66.1 | |||||
| ROIC % | -60.41 | |||||
| ROC (Joel Greenblatt) % | -108.88 | |||||
| ROCE % | -67.98 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 121 | |||||
| PB Ratio | 1.18 | |||||
| Price-to-Tangible-Book | 1.69 | |||||
| EV-to-EBIT | -1.14 | |||||
| EV-to-EBITDA | -1.25 | |||||
| EV-to-Revenue | 92.07 | |||||
| EV-to-FCF | -0.92 | |||||
| Price-to-Net-Current-Asset-Value | 4.23 | |||||
| Price-to-Net-Cash | 4.95 | |||||
| Earnings Yield (Greenblatt) % | -88.08 | |||||
| FCF Yield % | -74.64 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
iBio Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.163 | ||
| EPS (TTM) (€) | -6.087 | ||
| Beta | -0.58 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 3.5145 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 3.5145 - 3.5145 | ||
| Shares Outstanding (Mil) | 9.15 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
iBio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
iBio Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
iBio Inc Frequently Asked Questions
What is iBio Inc(FRA:0JV0)'s stock price today?
The current price of FRA:0JV0 is €3.51. The 52 week high of FRA:0JV0 is €3.51 and 52 week low is €3.51.
When is next earnings date of iBio Inc(FRA:0JV0)?
The next earnings date of iBio Inc(FRA:0JV0) is 2025-02-07 Est..
Does iBio Inc(FRA:0JV0) pay dividends? If so, how much?
iBio Inc(FRA:0JV0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers